Global Morphine Hydrochloride Market

Morphine Hydrochloride Comprehensive Study by Application (Pain Management, Diarrhea Suppressant, Cold and Cough Suppressant, Other), Drug Type (Anesthesia, Cough Suppressant, Diarrhea Suppressant, Others), Dosage Form (Injection, Oral Tablets, Other) Players and Region - Global Market Outlook to 2030

Morphine Hydrochloride Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Morphine Hydrochloride
Morphine hydrochloride is the hydrochloride salt of morphine. It is basically a type of morphine. Morphine is a naturally occurring opioid present in plants, animals, and humans. Morphine is primarily used to treat acute and chronic pain by working directly on the central nervous system (CNS) and reducing pain intensity. Morphine belongs to the class of narcotic analgesics, which alleviate pain by acting on the central nervous system. During the historical era, the market has grown due to increased demand for morphine in developed countries such as the United States and Europe. Morphine is the 155th most widely prescribed drug in the United States, according to the World Health Organization's list of essential medicines. Morphine is a pain reliever that comes in the form of extended-release capsules and extended-release tablets. Because of its high efficacy against pain and the above evidence, the global morphine demand is expected to expand at a healthy rate.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The key manufacturers are targeting the innovations of the products with better quality, and better technical characteristics, and also assist in providing and humanizing the after-sale service to the consumers. The key players are probable to keep a stronghold on the market over the anticipated period. The key players are accepting strategic decisions and are thinking about mergers and acquisitions to maintain their presence in the market. Analyst at AMA Research estimates that Asia Pacific Players will contribute the maximum growth to Global Morphine Hydrochloride market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Mallinckrodt Pharmaceuticals (United Kingdom), Pfizer Inc. (United States), Sun Pharmaceutical Industries Ltd (India), Allergan inc. (Ireland), Sandoz Canada Inc. (Canada), Mayne Pharma Group Limited (Australia), Daiichi Sankyo Inc. (Japan), Hikma Pharmaceuticals USA Inc. (United States), Mylan NV (United States) and Purdue Pharma L.P (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Verve Health Care Ltd (India), Alcaliber S.A. (Spain) and Others.

Segmentation Overview
AMA Research has segmented the market of Global Morphine Hydrochloride market by , Application (Pain Management, Diarrhea Suppressant, Cold and Cough Suppressant and Other) and Region.



On the basis of geography, the market of Morphine Hydrochloride has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Drug Type, the sub-segment i.e. Anesthesia will boost the Morphine Hydrochloride market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Dosage Form, the sub-segment i.e. Injection will boost the Morphine Hydrochloride market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Growth Drivers:
Rising Prevalence of Orthopedic Diseases and Chronic Pain and Most Widely Available and Low Priced Drug

Challenges:
Increasing Palliative Care Facilities

Restraints:
Various side Effects of the Drugs

Opportunities:
Growing Investment in the Healthcare Industry

In February 2020, Fresenius Kabi Canada announced the launch of Morphine Sulfate injection in a vial format. Fresenius Kabi Morphine is available in two presentations: 2 mg/mL and 10 mg/mL per vial.
According to FDA Take careto avoid dosing errors due to confusion between differentconcentrations and betweenmg and mL, which could result inaccidental overdose and death.

Key Target Audience
Pharmaceutical Companies, Healthcare Industry, Regulatory Bodies, Research Institutions and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Application
  • Pain Management
  • Diarrhea Suppressant
  • Cold and Cough Suppressant
  • Other
By Drug Type
  • Anesthesia
  • Cough Suppressant
  • Diarrhea Suppressant
  • Others

By Dosage Form
  • Injection
  • Oral Tablets
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence of Orthopedic Diseases and Chronic Pain
      • 3.2.2. Most Widely Available and Low Priced Drug
    • 3.3. Market Challenges
      • 3.3.1. Increasing Palliative Care Facilities
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Morphine Hydrochloride, by Application, Drug Type, Dosage Form and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Morphine Hydrochloride (Value)
      • 5.2.1. Global Morphine Hydrochloride by: Application (Value)
        • 5.2.1.1. Pain Management
        • 5.2.1.2. Diarrhea Suppressant
        • 5.2.1.3. Cold and Cough Suppressant
        • 5.2.1.4. Other
      • 5.2.2. Global Morphine Hydrochloride by: Drug Type (Value)
        • 5.2.2.1. Anesthesia
        • 5.2.2.2. Cough Suppressant
        • 5.2.2.3. Diarrhea Suppressant
        • 5.2.2.4. Others
      • 5.2.3. Global Morphine Hydrochloride by: Dosage Form (Value)
        • 5.2.3.1. Injection
        • 5.2.3.2. Oral Tablets
        • 5.2.3.3. Other
      • 5.2.4. Global Morphine Hydrochloride Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Morphine Hydrochloride: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Mallinckrodt Pharmaceuticals (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sun Pharmaceutical Industries Ltd (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Allergan inc. (Ireland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Sandoz Canada Inc. (Canada)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Mayne Pharma Group Limited (Australia)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Daiichi Sankyo Inc. (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Hikma Pharmaceuticals USA Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Mylan NV (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Purdue Pharma L.P (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Morphine Hydrochloride Sale, by Application, Drug Type, Dosage Form and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Morphine Hydrochloride (Value)
      • 7.2.1. Global Morphine Hydrochloride by: Application (Value)
        • 7.2.1.1. Pain Management
        • 7.2.1.2. Diarrhea Suppressant
        • 7.2.1.3. Cold and Cough Suppressant
        • 7.2.1.4. Other
      • 7.2.2. Global Morphine Hydrochloride by: Drug Type (Value)
        • 7.2.2.1. Anesthesia
        • 7.2.2.2. Cough Suppressant
        • 7.2.2.3. Diarrhea Suppressant
        • 7.2.2.4. Others
      • 7.2.3. Global Morphine Hydrochloride by: Dosage Form (Value)
        • 7.2.3.1. Injection
        • 7.2.3.2. Oral Tablets
        • 7.2.3.3. Other
      • 7.2.4. Global Morphine Hydrochloride Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Morphine Hydrochloride: by Application(USD Million)
  • Table 2. Morphine Hydrochloride Pain Management , by Region USD Million (2018-2023)
  • Table 3. Morphine Hydrochloride Diarrhea Suppressant , by Region USD Million (2018-2023)
  • Table 4. Morphine Hydrochloride Cold and Cough Suppressant , by Region USD Million (2018-2023)
  • Table 5. Morphine Hydrochloride Other , by Region USD Million (2018-2023)
  • Table 6. Morphine Hydrochloride: by Drug Type(USD Million)
  • Table 7. Morphine Hydrochloride Anesthesia , by Region USD Million (2018-2023)
  • Table 8. Morphine Hydrochloride Cough Suppressant , by Region USD Million (2018-2023)
  • Table 9. Morphine Hydrochloride Diarrhea Suppressant , by Region USD Million (2018-2023)
  • Table 10. Morphine Hydrochloride Others , by Region USD Million (2018-2023)
  • Table 11. Morphine Hydrochloride: by Dosage Form(USD Million)
  • Table 12. Morphine Hydrochloride Injection , by Region USD Million (2018-2023)
  • Table 13. Morphine Hydrochloride Oral Tablets , by Region USD Million (2018-2023)
  • Table 14. Morphine Hydrochloride Other , by Region USD Million (2018-2023)
  • Table 15. South America Morphine Hydrochloride, by Country USD Million (2018-2023)
  • Table 16. South America Morphine Hydrochloride, by Application USD Million (2018-2023)
  • Table 17. South America Morphine Hydrochloride, by Drug Type USD Million (2018-2023)
  • Table 18. South America Morphine Hydrochloride, by Dosage Form USD Million (2018-2023)
  • Table 19. Brazil Morphine Hydrochloride, by Application USD Million (2018-2023)
  • Table 20. Brazil Morphine Hydrochloride, by Drug Type USD Million (2018-2023)
  • Table 21. Brazil Morphine Hydrochloride, by Dosage Form USD Million (2018-2023)
  • Table 22. Argentina Morphine Hydrochloride, by Application USD Million (2018-2023)
  • Table 23. Argentina Morphine Hydrochloride, by Drug Type USD Million (2018-2023)
  • Table 24. Argentina Morphine Hydrochloride, by Dosage Form USD Million (2018-2023)
  • Table 25. Rest of South America Morphine Hydrochloride, by Application USD Million (2018-2023)
  • Table 26. Rest of South America Morphine Hydrochloride, by Drug Type USD Million (2018-2023)
  • Table 27. Rest of South America Morphine Hydrochloride, by Dosage Form USD Million (2018-2023)
  • Table 28. Asia Pacific Morphine Hydrochloride, by Country USD Million (2018-2023)
  • Table 29. Asia Pacific Morphine Hydrochloride, by Application USD Million (2018-2023)
  • Table 30. Asia Pacific Morphine Hydrochloride, by Drug Type USD Million (2018-2023)
  • Table 31. Asia Pacific Morphine Hydrochloride, by Dosage Form USD Million (2018-2023)
  • Table 32. China Morphine Hydrochloride, by Application USD Million (2018-2023)
  • Table 33. China Morphine Hydrochloride, by Drug Type USD Million (2018-2023)
  • Table 34. China Morphine Hydrochloride, by Dosage Form USD Million (2018-2023)
  • Table 35. Japan Morphine Hydrochloride, by Application USD Million (2018-2023)
  • Table 36. Japan Morphine Hydrochloride, by Drug Type USD Million (2018-2023)
  • Table 37. Japan Morphine Hydrochloride, by Dosage Form USD Million (2018-2023)
  • Table 38. India Morphine Hydrochloride, by Application USD Million (2018-2023)
  • Table 39. India Morphine Hydrochloride, by Drug Type USD Million (2018-2023)
  • Table 40. India Morphine Hydrochloride, by Dosage Form USD Million (2018-2023)
  • Table 41. South Korea Morphine Hydrochloride, by Application USD Million (2018-2023)
  • Table 42. South Korea Morphine Hydrochloride, by Drug Type USD Million (2018-2023)
  • Table 43. South Korea Morphine Hydrochloride, by Dosage Form USD Million (2018-2023)
  • Table 44. Taiwan Morphine Hydrochloride, by Application USD Million (2018-2023)
  • Table 45. Taiwan Morphine Hydrochloride, by Drug Type USD Million (2018-2023)
  • Table 46. Taiwan Morphine Hydrochloride, by Dosage Form USD Million (2018-2023)
  • Table 47. Australia Morphine Hydrochloride, by Application USD Million (2018-2023)
  • Table 48. Australia Morphine Hydrochloride, by Drug Type USD Million (2018-2023)
  • Table 49. Australia Morphine Hydrochloride, by Dosage Form USD Million (2018-2023)
  • Table 50. Rest of Asia-Pacific Morphine Hydrochloride, by Application USD Million (2018-2023)
  • Table 51. Rest of Asia-Pacific Morphine Hydrochloride, by Drug Type USD Million (2018-2023)
  • Table 52. Rest of Asia-Pacific Morphine Hydrochloride, by Dosage Form USD Million (2018-2023)
  • Table 53. Europe Morphine Hydrochloride, by Country USD Million (2018-2023)
  • Table 54. Europe Morphine Hydrochloride, by Application USD Million (2018-2023)
  • Table 55. Europe Morphine Hydrochloride, by Drug Type USD Million (2018-2023)
  • Table 56. Europe Morphine Hydrochloride, by Dosage Form USD Million (2018-2023)
  • Table 57. Germany Morphine Hydrochloride, by Application USD Million (2018-2023)
  • Table 58. Germany Morphine Hydrochloride, by Drug Type USD Million (2018-2023)
  • Table 59. Germany Morphine Hydrochloride, by Dosage Form USD Million (2018-2023)
  • Table 60. France Morphine Hydrochloride, by Application USD Million (2018-2023)
  • Table 61. France Morphine Hydrochloride, by Drug Type USD Million (2018-2023)
  • Table 62. France Morphine Hydrochloride, by Dosage Form USD Million (2018-2023)
  • Table 63. Italy Morphine Hydrochloride, by Application USD Million (2018-2023)
  • Table 64. Italy Morphine Hydrochloride, by Drug Type USD Million (2018-2023)
  • Table 65. Italy Morphine Hydrochloride, by Dosage Form USD Million (2018-2023)
  • Table 66. United Kingdom Morphine Hydrochloride, by Application USD Million (2018-2023)
  • Table 67. United Kingdom Morphine Hydrochloride, by Drug Type USD Million (2018-2023)
  • Table 68. United Kingdom Morphine Hydrochloride, by Dosage Form USD Million (2018-2023)
  • Table 69. Netherlands Morphine Hydrochloride, by Application USD Million (2018-2023)
  • Table 70. Netherlands Morphine Hydrochloride, by Drug Type USD Million (2018-2023)
  • Table 71. Netherlands Morphine Hydrochloride, by Dosage Form USD Million (2018-2023)
  • Table 72. Rest of Europe Morphine Hydrochloride, by Application USD Million (2018-2023)
  • Table 73. Rest of Europe Morphine Hydrochloride, by Drug Type USD Million (2018-2023)
  • Table 74. Rest of Europe Morphine Hydrochloride, by Dosage Form USD Million (2018-2023)
  • Table 75. MEA Morphine Hydrochloride, by Country USD Million (2018-2023)
  • Table 76. MEA Morphine Hydrochloride, by Application USD Million (2018-2023)
  • Table 77. MEA Morphine Hydrochloride, by Drug Type USD Million (2018-2023)
  • Table 78. MEA Morphine Hydrochloride, by Dosage Form USD Million (2018-2023)
  • Table 79. Middle East Morphine Hydrochloride, by Application USD Million (2018-2023)
  • Table 80. Middle East Morphine Hydrochloride, by Drug Type USD Million (2018-2023)
  • Table 81. Middle East Morphine Hydrochloride, by Dosage Form USD Million (2018-2023)
  • Table 82. Africa Morphine Hydrochloride, by Application USD Million (2018-2023)
  • Table 83. Africa Morphine Hydrochloride, by Drug Type USD Million (2018-2023)
  • Table 84. Africa Morphine Hydrochloride, by Dosage Form USD Million (2018-2023)
  • Table 85. North America Morphine Hydrochloride, by Country USD Million (2018-2023)
  • Table 86. North America Morphine Hydrochloride, by Application USD Million (2018-2023)
  • Table 87. North America Morphine Hydrochloride, by Drug Type USD Million (2018-2023)
  • Table 88. North America Morphine Hydrochloride, by Dosage Form USD Million (2018-2023)
  • Table 89. United States Morphine Hydrochloride, by Application USD Million (2018-2023)
  • Table 90. United States Morphine Hydrochloride, by Drug Type USD Million (2018-2023)
  • Table 91. United States Morphine Hydrochloride, by Dosage Form USD Million (2018-2023)
  • Table 92. Canada Morphine Hydrochloride, by Application USD Million (2018-2023)
  • Table 93. Canada Morphine Hydrochloride, by Drug Type USD Million (2018-2023)
  • Table 94. Canada Morphine Hydrochloride, by Dosage Form USD Million (2018-2023)
  • Table 95. Mexico Morphine Hydrochloride, by Application USD Million (2018-2023)
  • Table 96. Mexico Morphine Hydrochloride, by Drug Type USD Million (2018-2023)
  • Table 97. Mexico Morphine Hydrochloride, by Dosage Form USD Million (2018-2023)
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Morphine Hydrochloride: by Application(USD Million)
  • Table 109. Morphine Hydrochloride Pain Management , by Region USD Million (2025-2030)
  • Table 110. Morphine Hydrochloride Diarrhea Suppressant , by Region USD Million (2025-2030)
  • Table 111. Morphine Hydrochloride Cold and Cough Suppressant , by Region USD Million (2025-2030)
  • Table 112. Morphine Hydrochloride Other , by Region USD Million (2025-2030)
  • Table 113. Morphine Hydrochloride: by Drug Type(USD Million)
  • Table 114. Morphine Hydrochloride Anesthesia , by Region USD Million (2025-2030)
  • Table 115. Morphine Hydrochloride Cough Suppressant , by Region USD Million (2025-2030)
  • Table 116. Morphine Hydrochloride Diarrhea Suppressant , by Region USD Million (2025-2030)
  • Table 117. Morphine Hydrochloride Others , by Region USD Million (2025-2030)
  • Table 118. Morphine Hydrochloride: by Dosage Form(USD Million)
  • Table 119. Morphine Hydrochloride Injection , by Region USD Million (2025-2030)
  • Table 120. Morphine Hydrochloride Oral Tablets , by Region USD Million (2025-2030)
  • Table 121. Morphine Hydrochloride Other , by Region USD Million (2025-2030)
  • Table 122. South America Morphine Hydrochloride, by Country USD Million (2025-2030)
  • Table 123. South America Morphine Hydrochloride, by Application USD Million (2025-2030)
  • Table 124. South America Morphine Hydrochloride, by Drug Type USD Million (2025-2030)
  • Table 125. South America Morphine Hydrochloride, by Dosage Form USD Million (2025-2030)
  • Table 126. Brazil Morphine Hydrochloride, by Application USD Million (2025-2030)
  • Table 127. Brazil Morphine Hydrochloride, by Drug Type USD Million (2025-2030)
  • Table 128. Brazil Morphine Hydrochloride, by Dosage Form USD Million (2025-2030)
  • Table 129. Argentina Morphine Hydrochloride, by Application USD Million (2025-2030)
  • Table 130. Argentina Morphine Hydrochloride, by Drug Type USD Million (2025-2030)
  • Table 131. Argentina Morphine Hydrochloride, by Dosage Form USD Million (2025-2030)
  • Table 132. Rest of South America Morphine Hydrochloride, by Application USD Million (2025-2030)
  • Table 133. Rest of South America Morphine Hydrochloride, by Drug Type USD Million (2025-2030)
  • Table 134. Rest of South America Morphine Hydrochloride, by Dosage Form USD Million (2025-2030)
  • Table 135. Asia Pacific Morphine Hydrochloride, by Country USD Million (2025-2030)
  • Table 136. Asia Pacific Morphine Hydrochloride, by Application USD Million (2025-2030)
  • Table 137. Asia Pacific Morphine Hydrochloride, by Drug Type USD Million (2025-2030)
  • Table 138. Asia Pacific Morphine Hydrochloride, by Dosage Form USD Million (2025-2030)
  • Table 139. China Morphine Hydrochloride, by Application USD Million (2025-2030)
  • Table 140. China Morphine Hydrochloride, by Drug Type USD Million (2025-2030)
  • Table 141. China Morphine Hydrochloride, by Dosage Form USD Million (2025-2030)
  • Table 142. Japan Morphine Hydrochloride, by Application USD Million (2025-2030)
  • Table 143. Japan Morphine Hydrochloride, by Drug Type USD Million (2025-2030)
  • Table 144. Japan Morphine Hydrochloride, by Dosage Form USD Million (2025-2030)
  • Table 145. India Morphine Hydrochloride, by Application USD Million (2025-2030)
  • Table 146. India Morphine Hydrochloride, by Drug Type USD Million (2025-2030)
  • Table 147. India Morphine Hydrochloride, by Dosage Form USD Million (2025-2030)
  • Table 148. South Korea Morphine Hydrochloride, by Application USD Million (2025-2030)
  • Table 149. South Korea Morphine Hydrochloride, by Drug Type USD Million (2025-2030)
  • Table 150. South Korea Morphine Hydrochloride, by Dosage Form USD Million (2025-2030)
  • Table 151. Taiwan Morphine Hydrochloride, by Application USD Million (2025-2030)
  • Table 152. Taiwan Morphine Hydrochloride, by Drug Type USD Million (2025-2030)
  • Table 153. Taiwan Morphine Hydrochloride, by Dosage Form USD Million (2025-2030)
  • Table 154. Australia Morphine Hydrochloride, by Application USD Million (2025-2030)
  • Table 155. Australia Morphine Hydrochloride, by Drug Type USD Million (2025-2030)
  • Table 156. Australia Morphine Hydrochloride, by Dosage Form USD Million (2025-2030)
  • Table 157. Rest of Asia-Pacific Morphine Hydrochloride, by Application USD Million (2025-2030)
  • Table 158. Rest of Asia-Pacific Morphine Hydrochloride, by Drug Type USD Million (2025-2030)
  • Table 159. Rest of Asia-Pacific Morphine Hydrochloride, by Dosage Form USD Million (2025-2030)
  • Table 160. Europe Morphine Hydrochloride, by Country USD Million (2025-2030)
  • Table 161. Europe Morphine Hydrochloride, by Application USD Million (2025-2030)
  • Table 162. Europe Morphine Hydrochloride, by Drug Type USD Million (2025-2030)
  • Table 163. Europe Morphine Hydrochloride, by Dosage Form USD Million (2025-2030)
  • Table 164. Germany Morphine Hydrochloride, by Application USD Million (2025-2030)
  • Table 165. Germany Morphine Hydrochloride, by Drug Type USD Million (2025-2030)
  • Table 166. Germany Morphine Hydrochloride, by Dosage Form USD Million (2025-2030)
  • Table 167. France Morphine Hydrochloride, by Application USD Million (2025-2030)
  • Table 168. France Morphine Hydrochloride, by Drug Type USD Million (2025-2030)
  • Table 169. France Morphine Hydrochloride, by Dosage Form USD Million (2025-2030)
  • Table 170. Italy Morphine Hydrochloride, by Application USD Million (2025-2030)
  • Table 171. Italy Morphine Hydrochloride, by Drug Type USD Million (2025-2030)
  • Table 172. Italy Morphine Hydrochloride, by Dosage Form USD Million (2025-2030)
  • Table 173. United Kingdom Morphine Hydrochloride, by Application USD Million (2025-2030)
  • Table 174. United Kingdom Morphine Hydrochloride, by Drug Type USD Million (2025-2030)
  • Table 175. United Kingdom Morphine Hydrochloride, by Dosage Form USD Million (2025-2030)
  • Table 176. Netherlands Morphine Hydrochloride, by Application USD Million (2025-2030)
  • Table 177. Netherlands Morphine Hydrochloride, by Drug Type USD Million (2025-2030)
  • Table 178. Netherlands Morphine Hydrochloride, by Dosage Form USD Million (2025-2030)
  • Table 179. Rest of Europe Morphine Hydrochloride, by Application USD Million (2025-2030)
  • Table 180. Rest of Europe Morphine Hydrochloride, by Drug Type USD Million (2025-2030)
  • Table 181. Rest of Europe Morphine Hydrochloride, by Dosage Form USD Million (2025-2030)
  • Table 182. MEA Morphine Hydrochloride, by Country USD Million (2025-2030)
  • Table 183. MEA Morphine Hydrochloride, by Application USD Million (2025-2030)
  • Table 184. MEA Morphine Hydrochloride, by Drug Type USD Million (2025-2030)
  • Table 185. MEA Morphine Hydrochloride, by Dosage Form USD Million (2025-2030)
  • Table 186. Middle East Morphine Hydrochloride, by Application USD Million (2025-2030)
  • Table 187. Middle East Morphine Hydrochloride, by Drug Type USD Million (2025-2030)
  • Table 188. Middle East Morphine Hydrochloride, by Dosage Form USD Million (2025-2030)
  • Table 189. Africa Morphine Hydrochloride, by Application USD Million (2025-2030)
  • Table 190. Africa Morphine Hydrochloride, by Drug Type USD Million (2025-2030)
  • Table 191. Africa Morphine Hydrochloride, by Dosage Form USD Million (2025-2030)
  • Table 192. North America Morphine Hydrochloride, by Country USD Million (2025-2030)
  • Table 193. North America Morphine Hydrochloride, by Application USD Million (2025-2030)
  • Table 194. North America Morphine Hydrochloride, by Drug Type USD Million (2025-2030)
  • Table 195. North America Morphine Hydrochloride, by Dosage Form USD Million (2025-2030)
  • Table 196. United States Morphine Hydrochloride, by Application USD Million (2025-2030)
  • Table 197. United States Morphine Hydrochloride, by Drug Type USD Million (2025-2030)
  • Table 198. United States Morphine Hydrochloride, by Dosage Form USD Million (2025-2030)
  • Table 199. Canada Morphine Hydrochloride, by Application USD Million (2025-2030)
  • Table 200. Canada Morphine Hydrochloride, by Drug Type USD Million (2025-2030)
  • Table 201. Canada Morphine Hydrochloride, by Dosage Form USD Million (2025-2030)
  • Table 202. Mexico Morphine Hydrochloride, by Application USD Million (2025-2030)
  • Table 203. Mexico Morphine Hydrochloride, by Drug Type USD Million (2025-2030)
  • Table 204. Mexico Morphine Hydrochloride, by Dosage Form USD Million (2025-2030)
  • Table 205. Research Programs/Design for This Report
  • Table 206. Key Data Information from Secondary Sources
  • Table 207. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Morphine Hydrochloride: by Application USD Million (2018-2023)
  • Figure 5. Global Morphine Hydrochloride: by Drug Type USD Million (2018-2023)
  • Figure 6. Global Morphine Hydrochloride: by Dosage Form USD Million (2018-2023)
  • Figure 7. South America Morphine Hydrochloride Share (%), by Country
  • Figure 8. Asia Pacific Morphine Hydrochloride Share (%), by Country
  • Figure 9. Europe Morphine Hydrochloride Share (%), by Country
  • Figure 10. MEA Morphine Hydrochloride Share (%), by Country
  • Figure 11. North America Morphine Hydrochloride Share (%), by Country
  • Figure 12. Global Morphine Hydrochloride share by Players 2023 (%)
  • Figure 13. Global Morphine Hydrochloride share by Players (Top 3) 2023(%)
  • Figure 14. Global Morphine Hydrochloride share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Mallinckrodt Pharmaceuticals (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 17. Mallinckrodt Pharmaceuticals (United Kingdom) Revenue: by Geography 2023
  • Figure 18. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 20. Sun Pharmaceutical Industries Ltd (India) Revenue, Net Income and Gross profit
  • Figure 21. Sun Pharmaceutical Industries Ltd (India) Revenue: by Geography 2023
  • Figure 22. Allergan inc. (Ireland) Revenue, Net Income and Gross profit
  • Figure 23. Allergan inc. (Ireland) Revenue: by Geography 2023
  • Figure 24. Sandoz Canada Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 25. Sandoz Canada Inc. (Canada) Revenue: by Geography 2023
  • Figure 26. Mayne Pharma Group Limited (Australia) Revenue, Net Income and Gross profit
  • Figure 27. Mayne Pharma Group Limited (Australia) Revenue: by Geography 2023
  • Figure 28. Daiichi Sankyo Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 29. Daiichi Sankyo Inc. (Japan) Revenue: by Geography 2023
  • Figure 30. Hikma Pharmaceuticals USA Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Hikma Pharmaceuticals USA Inc. (United States) Revenue: by Geography 2023
  • Figure 32. Mylan NV (United States) Revenue, Net Income and Gross profit
  • Figure 33. Mylan NV (United States) Revenue: by Geography 2023
  • Figure 34. Purdue Pharma L.P (United States) Revenue, Net Income and Gross profit
  • Figure 35. Purdue Pharma L.P (United States) Revenue: by Geography 2023
  • Figure 36. Global Morphine Hydrochloride: by Application USD Million (2025-2030)
  • Figure 37. Global Morphine Hydrochloride: by Drug Type USD Million (2025-2030)
  • Figure 38. Global Morphine Hydrochloride: by Dosage Form USD Million (2025-2030)
  • Figure 39. South America Morphine Hydrochloride Share (%), by Country
  • Figure 40. Asia Pacific Morphine Hydrochloride Share (%), by Country
  • Figure 41. Europe Morphine Hydrochloride Share (%), by Country
  • Figure 42. MEA Morphine Hydrochloride Share (%), by Country
  • Figure 43. North America Morphine Hydrochloride Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Mallinckrodt Pharmaceuticals (United Kingdom)
  • Pfizer Inc. (United States)
  • Sun Pharmaceutical Industries Ltd (India)
  • Allergan inc. (Ireland)
  • Sandoz Canada Inc. (Canada)
  • Mayne Pharma Group Limited (Australia)
  • Daiichi Sankyo Inc. (Japan)
  • Hikma Pharmaceuticals USA Inc. (United States)
  • Mylan NV (United States)
  • Purdue Pharma L.P (United States)
Additional players considered in the study are as follows:
Verve Health Care Ltd (India) , Alcaliber S.A. (Spain) , Others
Select User Access Type

Key Highlights of Report


Apr 2024 220 Pages 53 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Morphine Hydrochloride Market Quantitative research analysis
Global Morphine Hydrochloride Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Mallinckrodt Pharmaceuticals (United Kingdom), Pfizer Inc. (United States), Sun Pharmaceutical Industries Ltd (India), Allergan inc. (Ireland), Sandoz Canada Inc. (Canada), Mayne Pharma Group Limited (Australia), Daiichi Sankyo Inc. (Japan), Hikma Pharmaceuticals USA Inc. (United States), Mylan NV (United States) and Purdue Pharma L.P (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"" is seen as one of major influencing trends for Morphine Hydrochloride Market during projected period 2023-2030.
The Morphine Hydrochloride market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Morphine Hydrochloride Market Report?

Have a Query? Click Here

Other Related Reports

Antihypertensives Comprehensive Study by Type (Diuretics, Angiotensin Converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (ARBs), Beta Blockers, Vasodilators, Alpha Blockers, Renin Inhi...
$ 3650
Dysmenorrhea Treatment Comprehensive Study by Application (Primary Dysmenorrhea, Secondary Dysmenorrhea), Treatment (Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Hormonal Therapy), Drug Used (Ibup...
$ 3450
Silk Protein Comprehensive Study by Type (Fibroin, Sericin), Nature (Recyclable, Biodegradable, Biocompatible, Others), Industry Verticals (Cosmetics, Personal Care, Medical, Others), Sales Channel (...
$ 3500
Alectinib Drugs Comprehensive Study by Application (Hospitals, Clinics, Others), Capacity (1 Capsule, 140 Capsules, 28 Capsules, 26 Capsules), End Use (Unresectable NSCLC, Advanced NSCLC, Recurrent N...
$ 3500
Protein Stability Analysis Comprehensive Study by Type (Reagents and Assay Kits, Instruments, Consumable and Accessories, Software), Technique (Chromatography, Spectroscopy, Surface Plasma Resonance ...
$ 3750
Aerosols Budesonide Comprehensive Study by Application (Hospitals, Specialty Clinics, Over-the-Counter (OTC)), Distribution Channel (Online (E-Commerce Websites, Third Party Websites), Offline (Retai...
$ 3750